Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
INSPIRATION Investigators, Sadeghipour Parham, Talasaz Azita H, Rashidi Farid, Sharif-Kashani Babak, Beigmohammadi Mohammad Taghi, Farrokhpour Mohsen, Sezavar Seyed Hashem, Payandemehr Pooya, Dabbagh Ali, Moghadam Keivan Gohari, Jamalkhani Sepehr, Khalili Hossein, Yadollahzadeh Mahdi, Riahi Taghi, Rezaeifar Parisa, Tahamtan Ouria, Matin Samira, Abedini Atefeh, Lookzadeh Somayeh, Rahmani Hamid, Zoghi Elnaz, Mohammadi Keyhan, Sadeghipour Pardis, Abri Homa, Tabrizi Sanaz, Mousavian Seyed Masoud, Shahmirzaei Shaghayegh, Bakhshandeh Hooman, Amin Ahmad, Rafiee Farnaz, Baghizadeh Elahe, Mohebbi Bahram, Parhizgar Seyed Ehsan, Aliannejad Rasoul, Eslami Vahid, Kashefizadeh Alireza, Kakavand Hessam, Hosseini Seyed Hossein, Shafaghi Shadi, Ghazi Samrand Fattah, Najafi Atabak, Jimenez David, Gupta Aakriti, Madhavan Mahesh V, Sethi Sanjum S, Parikh Sahil A, Monreal Manuel, Hadavand Naser, Hajighasemi Alireza, Maleki Majid, Sadeghian Saeed, Piazza Gregory, Kirtane Ajay J, Van Tassell Benjamin W, Dobesh Paul P, Stone Gregg W, Lip Gregory Y H, Krumholz Harlan M, Goldhaber Samuel Z, Bikdeli Behnood
Аннотация
OBJECTIVE: To evaluate the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU).
DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized trial with a 2 × 2 factorial design performed in 10 academic centers in Iran comparing intermediate-dose vs standard-dose prophylactic anticoagulation (first hypothesis) and statin therapy vs matching placebo (second hypothesis; not reported in this article) among adult patients admitted to the ICU with COVID-19. Patients were recruited between July 29, 2020, and November 19, 2020. The final follow-up date for the 30-day primary outcome was December 19, 2020.
INTERVENTIONS: Intermediate-dose (enoxaparin, 1 mg/kg daily) (n = 276) vs standard prophylactic anticoagulation (enoxaparin, 40 mg daily) (n = 286), with modification according to body weight and creatinine clearance. The assigned treatments were planned to be continued until completion of 30-day follow-up.
MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was a composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days, assessed in randomized patients who met the eligibility criteria and received at least 1 dose of the assigned treatment. Prespecified safety outcomes included major bleeding according to the Bleeding Academic Research Consortium (type 3 or 5 definition), powered for noninferiority (a noninferiority margin of 1.8 based on odds ratio), and severe thrombocytopenia (platelet count <20 ×103/µL). All outcomes were blindly adjudicated.
RESULTS: Among 600 randomized patients, 562 (93.7%) were included in the primary analysis (median [interquartile range] age, 62 [50-71] years; 237 [42.2%] women). The primary efficacy outcome occurred in 126 patients (45.7%) in the intermediate-dose group and 126 patients (44.1%) in the standard-dose prophylaxis group (absolute risk difference, 1.5% [95% CI, -6.6% to 9.8%]; odds ratio, 1.06 [95% CI, 0.76-1.48]; P = .70). Major bleeding occurred in 7 patients (2.5%) in the intermediate-dose group and 4 patients (1.4%) in the standard-dose prophylaxis group (risk difference, 1.1% [1-sided 97.5% CI, -∞ to 3.4%]; odds ratio, 1.83 [1-sided 97.5% CI, 0.00-5.93]), not meeting the noninferiority criteria (P for noninferiority >.99). Severe thrombocytopenia occurred only in patients assigned to the intermediate-dose group (6 vs 0 patients; risk difference, 2.2% [95% CI, 0.4%-3.8%]; P = .01).
CONCLUSIONS AND RELEVANCE: Among patients admitted to the ICU with COVID-19, intermediate-dose prophylactic anticoagulation, compared with standard-dose prophylactic anticoagulation, did not result in a significant difference in the primary outcome of a composite of adjudicated venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality within 30 days. These results do not support the routine empirical use of intermediate-dose prophylactic anticoagulation in unselected patients admitted to the ICU with COVID-19.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04486508.